8-K: Stoke Therapeutics Q1 2026 Results & Zorevunersen Data Update

Stoke Therapeutics reported Q1 2026 financial results, highlighting positive 4-year data for zorevunersen in Dravet syndrome and providing updates on Phase 3 enrollment.

Summary

• Stoke Therapeutics announced its financial results for the first quarter ended March 31, 2026.
• The company presented new 4-year longitudinal data from Phase 1/2a open-label extension studies for zorevunersen, an investigational treatment for Dravet syndrome.
• These data show statistically significant improvements in cognition and behavior, along with continued seizure reduction durability.
• Enrollment for the Phase 3 EMPEROR study is expected to complete in June 2026, with a data readout anticipated in mid-2027.
• The company had $411.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, sufficient to fund operations into 2028.
• This includes $80.7 million raised through ATM sales in Q1 2026.
• Revenue for Q1 2026 was $6.2 million, a decrease from $158.6 million in Q1 2025, primarily due to a one-time IP license recognition in the prior year.
• Net loss for Q1 2026 was $50.0 million ($0.79 per share), compared to a net income of $112.9 million ($1.90 per diluted share) in Q1 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update due to strong clinical data for zorevunersen and a robust cash position, despite expected financial losses and revenue decline from prior year non-recurring items.

Positives

• New 4-year data from zorevunersen OLE studies show statistically significant improvements in cognition and behavior, and continued durability in seizure reductions.
• Zorevunersen has been generally well tolerated, with some patients treated for over 5 years.
• Enrollment for the Phase 3 EMPEROR study is on track to complete in June 2026.
• The company possesses $411.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2028.
• The company raised $80.7 million through selective ATM sales in Q1 2026.
• Zorevunersen has received Orphan Drug Designation and Breakthrough Therapy Designation from the FDA.
• The first patient was dosed in the Phase 1 OSPREY study for STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in February 2026.
• Lead optimization is underway to identify a clinical candidate for SYNGAP1 in 2026.

Negatives

• Revenue for Q1 2026 was $6.2 million, a significant decrease from $158.6 million in Q1 2025, due to the prior year's recognition of a $150.8 million IP license performance obligation.
• The company reported a net loss of $50.0 million ($0.79 per share) for Q1 2026, compared to a net income of $112.9 million ($1.90 per diluted share) in Q1 2025.
• Research and development expenses increased by $7.0 million to $39.7 million in Q1 2026 compared to Q1 2025.
• Sales, general and administrative expenses increased by $5.3 million to $20.0 million in Q1 2026 compared to Q1 2025.

Risks

• Elevated CSF protein lab values occurred in approximately 94% of patients, with 59% classified as a treatment-emergent adverse event, though no serious clinical manifestations have been associated.
• The development of zorevunersen and STK-002 is subject to the inherent risks and uncertainties of clinical trials, regulatory approvals, and commercialization.
• The company's ability to advance, obtain regulatory approval for, and commercialize its product candidates is subject to significant risks.
• If partners breach or terminate collaborations, the company may not obtain anticipated benefits.
• Positive results in early-stage clinical trials may not be replicated in subsequent trials.
• The company faces risks related to its reliance on its partners, including Biogen.
• The company's future results may differ materially from forward-looking statements due to various risks and uncertainties.
• The company's Annual Report on Form 10-K and other SEC filings detail additional risks and uncertainties.

Future Outlook

The company expects to complete enrollment of the Phase 3 EMPEROR study in June 2026, with a data readout in mid-2027, supporting a rolling U.S. NDA submission planned for Q1 2027. The company's cash position is expected to fund operations into 2028. Commercial preparedness is a focus, with a potential U.S. launch in early 2028.

Management Comments

• "These new 4-year OLE data suggest that zorevunersen may change the course of Dravet syndrome by providing children with durable reductions in seizures and the possibility of a more neurotypical development path."
• "We look forward to results from our pivotal Phase 3 study, which is on track to complete enrollment of approximately 150 patients in June to support a data readout in mid-2027."
• "As we continue to see this study through to completion, our focus turns increasingly to commercial preparedness and bringing zorevunersen to patients while also building our pipeline for the future."
• "All of this is supported by our strong financial position taking us through to a potential U.S. launch in early 2028."

Industry Context

StockSavvy.ai notes that Stoke Therapeutics' update on zorevunersen aligns with the broader trend in the pharmaceutical industry towards developing disease-modifying therapies for rare genetic disorders, particularly in the neurology space. The company's progress in Dravet syndrome and ADOA highlights the potential of RNA medicine to address underlying genetic causes.

Comparison to Industry Standards

• The 4-year durability of seizure reduction and cognitive/behavioral improvements for zorevunersen in Dravet syndrome, where current treatments often fail to achieve significant seizure reduction, is a notable positive.
• The cash runway extending into 2028 is strong for a clinical-stage biotechnology company, providing ample time for Phase 3 development and regulatory submissions.
• The revenue decrease is explained by a non-recurring item in the prior year, making direct comparison difficult but highlighting the typical revenue profile of a clinical-stage biotech company reliant on milestones or upfront payments.
• The net loss is consistent with the significant investment required for late-stage clinical development of novel therapeutics.

Stakeholder Impact

• Shareholders: Positive impact from promising clinical data and extended cash runway, offset by expected continued net losses.
• Patients with Dravet Syndrome: Potential for a disease-modifying treatment with durable seizure reduction and cognitive/behavioral improvements.
• Patients with ADOA: Progress in the Phase 1 OSPREY study for STK-002 offers hope for a first-in-class disease-modifying therapy.
• Employees: Continued investment in R&D and SG&A suggests ongoing growth and development opportunities.
• Partners (Biogen): Continued progress in the zorevunersen collaboration is beneficial.

Next Steps

• Complete enrollment of approximately 150 patients in the Phase 3 EMPEROR study in June 2026.
• Achieve a data readout from the Phase 3 EMPEROR study in mid-2027.
• Initiate rolling U.S. NDA submission for zorevunersen in Q1 2027.
• Complete enrollment in Europe for the Phase 3 EMPEROR study in Q3 2026.
• Continue dose escalation for the first four cohorts of the OSPREY study through 2026 and early 2027.
• Identify a clinical candidate for SYNGAP1 treatment in 2026.
• Focus on commercial preparedness for zorevunersen.

Key Dates

Recommendation

The company presents strong clinical data and a solid financial position, but the path to commercialization for zorevunersen is still lengthy, with a data readout in mid-2027 and potential launch in early 2028. While promising, the inherent risks of drug development and regulatory approval warrant a 'hold' recommendation until further de-risking events occur.

Keywords

Stoke Therapeutics, Zorevunersen, Dravet Syndrome, RNA Medicine, Biotechnology, Clinical Trials, Phase 3, Financial Results